Dr.SREEKANTH THOTA

@vaagdevipharmacy.com

HOD & PROFESSOR, PHARMACEUTICAL CHEMISTRY & ANALYSIS
VAAGDEVI COLLEGE OF PHARMACY

Dr.SREEKANTH THOTA


                           Download Compact PDF  
https://researchid.co/sri_237
I currently serve as a Professor at the VAAGDEVI COLLEGE OF PHARMACY, Ramnagar, Hanamkonda, Warangal, Telangana, India. My academic journey began with a Bachelor's degree in Pharmacy from Kakatiya University, Warangal, India, followed by a Master's degree in Pharmacy from Rajiv Gandhi University of Health Sciences in Bangalore, India. Subsequently, I earned my PhD from Jawaharlal Nehru Technological University Hyderabad in 2011.
In recognition of my research endeavors, I was honored with the Research Promotion Scheme award sponsored by AICTE, New Delhi in 2012. Furthering my academic pursuits, I pursued postdoctoral research at Colorado State University in the USA during 2013. I was honored with the CAPES-Fiocruz Visiting Researcher award in 2013 and worked as a Visiting Research Scientist at CDTS-Fiocruz & LASSBio (UFRJ), Brazil from 2014 to 2018. My research focus is on Drug discovery, Drug design, and Medicinal chemistry with over 45 publications.

EDUCATION

Education: Jawaharlal Nehru Technological University of Hyderabad, Hyderabad, Telangana, India.
Ph.D. in (Pharmaceutical Sciences), 2007-2011
Advisor: Prof. Subhas S Karki

Rajiv Gandhi University of Health Sciences (K. L. E. S. College of Pharmacy), Bengaluru, Karnataka, India.
M. Pharmacy-Pharmaceutical Chemistry, 2004-2006

Kakatiya University (Talla Padmavathi College of Pharmacy), Warangal, Telangana, India.
B. Pharmacy, 1999-2003

RESEARCH, TEACHING, or OTHER INTERESTS

Drug Discovery, Biochemistry, Genetics and Molecular Biology, Chemistry, Cancer Research
37

Scopus Publications

1721

Scholar Citations

18

Scholar h-index

29

Scholar i10-index

Scopus Publications

  • Structure-property relationship studies of 3-acyl-substituted furans: The serendipitous identification and characterization of a new non-classical hydrogen bond donor moiety
    Daniel A. Rodrigues, Pedro de Sena M. Pinheiro, Fernanda S. Sagrillo, Maria Clara R. Freitas, Marina A. Alves, Sreekanth Thota, Luzineide W. Tinoco, Alvicler Magalhães, Carlos M. R. Sant’Anna, Carlos A. M. Fraga
    New Journal of Chemistry, 2020
    A serendipitous identification and characterization of a new non-classical hydrogen bond donor moiety found in N-acylhydrazones containing 3-acyl-substituted furan subunit is presented.
  • Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors
    Daniel A. Rodrigues, Fabiana S. Guerra, Fernanda S. Sagrillo, Pedro de Sena M. Pinheiro, Marina A. Alves, Sreekanth Thota, Lorrane S. Chaves, Carlos M. R. Sant'Anna, Patrícia D. Fernandes, Carlos A. M. Fraga
    Chemmedchem, 2020
    Targeting histone deacetylases (HDACs) and phosphatidylinositol 3‐kinases (PI3Ks) is a very promising approach for cancer treatment. This manuscript describes the design, synthesis, in vitro pharmacological profile, and molecular modeling of a novel class of N‐acylhydrazone (NAH) derivatives that act as HDAC6/8 and PI3Kα dual inhibitors. The surprising selectivity for PI3Kα may be related to differences in the conformation in the active site. Cellular studies showed that these compounds act in HDAC6 inhibition and the PI3/K/AKT/mTOR pathway. The compounds that are selective for inhibition of HDAC6/8 and inhibit PI3Kα show potential for the treatment of cancer.
  • The use of conformational restriction in medicinal chemistry
    Pedro de Sena M. Pinheiro, Daniel A. Rodrigues, Rodolfo do Couto Maia, Sreekanth Thota, Carlos A.M. Fraga
    Current Topics in Medicinal Chemistry, 2019
    During the early preclinical phase, from hit identification and optimization to a lead compound, several medicinal chemistry strategies can be used to improve potency and/or selectivity. The conformational restriction is one of these approaches. It consists of introducing some specific structural constraints in a lead candidate to reduce the overall number of possible conformations in order to favor the adoption of a bioactive conformation and, as a consequence, molecular recognition by the target receptor. In this work, we focused on the application of the conformational restriction strategy in the last five years for the optimization of hits and/or leads of several important classes of therapeutic targets in the drug discovery field. Thus, we recognize the importance of several kinase inhibitors to the current landscape of drug development for cancer therapy and the use of G-protein Coupled Receptor (GPCR) modulators. Several other targets are also highlighted, such as the class of epigenetic drugs. Therefore, the possibility of exploiting conformational restriction as a tool to increase the potency and selectivity and promote changes in the intrinsic activity of some ligands intended to act on many different targets makes this strategy of structural modification valuable for the discovery of novel drug candidates.
  • N-Acylhydrazones as drugs
    Sreekanth Thota, Daniel A. Rodrigues, Pedro de Sena Murteira Pinheiro, Lídia M. Lima, Carlos A.M. Fraga, Eliezer J. Barreiro
    Bioorganic and Medicinal Chemistry Letters, 2018
  • Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
    Sreekanth Thota, Daniel A. Rodrigues, Debbie C. Crans, Eliezer J. Barreiro
    Journal of Medicinal Chemistry, 2018
    Metal based therapeutics are a precious class of drugs in oncology research that include examples of theranostic drugs, which are active in both diagnostic, specifically imaging, and therapeutics applications. Ruthenium compounds have shown selective bioactivity and the ability to overcome the resistance that platinum-based therapeutics face, making them effective oncotherapeutic competitors in rational drug invention approaches. The development of antineoplastic ruthenium therapeutics is of particular interest because ruthenium containing complexes NAMI-A, KP1019, and KP1339 entered clinical trials and DW1/2 is in preclinical levels. The very robust, conformationally rigid organometallic Ru(II) compound DW1/2 is a protein kinase inhibitor and presents new Ru(II) compound designs as anticancer agents. Over the recent years, numerous strategies have been used to encapsulate Ru(II) derived compounds in a nanomaterial system, improving their targeting and delivery into neoplastic cells. A new photodynamic therapy based Ru(II) therapeutic, TLD-1433, has also entered clinical trials. Ru(II)-based compounds can also be photosensitizers for photodynamic therapy, which has proven to be an effective new, alternative, and noninvasive oncotherapy modality.
  • Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40)
    Daniel Alencar Rodrigues, Pedro de Sena Murteira Pinheiro, Thayssa Tavares da Silva Cunha Ferreira, Sreekanth Thota, Carlos Alberto Manssour Fraga
    Chemical Biology and Drug Design, 2018
    G‐protein‐coupled receptor 40 (GPR40) was recently identified as an interesting target for treatment of type 2 diabetes. The high level of expression in pancreatic beta cells and the dependence of glucose on stimulating the secretion of insulin led to great excitement in this field. The identification of this target was followed by the development of a series of agonists with great potential for the treatment of diabetes. All known agonists have the presence of a pharmacophoric carboxylic acid group in their structure, which makes several polar interactions at the binding site of this receptor. In this report, we provide a review of the structure–activity relationships of GPR40 agonists with a focus on the main strategies of medicinal chemistry used to develop each one of the main structural patterns exploited for this purpose. Additionally, we provide a general model for the design of GPR40 ligands that can help researchers to follow up some strategies and implement them in the development of novel agonists of this receptor.
  • Drug discovery for paediatric chagas disease
    Sreekanth Thota, Carlos M. Morel
    Mini Reviews in Medicinal Chemistry, 2018
    Chagas disease is caused by the parasite Trypanosoma cruzi and is regularly found among particular people living in Central and South America. Paediatric Chagas disease occurs in 1-10% of infants of infected mothers. The major important point considered in the treatment of congenital Chagas disease focuses on killing the parasite in acute infection and managing signs and symptoms in later stages. Nowadays, two drugs benznidazole and nifurtimox are currently available in the market for the treatment of paediatric Chagas disease.
  • Recent advances in development of polyphenols as anticancer agents
    Sreekanth Thota, Daniel Alencar Rodrigues, Eliezer J. Barreiro
    Mini Reviews in Medicinal Chemistry, 2018
    Still now, for many forms of the disseminated cancers there is no curative therapy available. The discovery of novel active chemotherapeutic agents is largely essential to overcome this problem. Natural compounds polyphenols are mainly characterized by a huge structural variance; they can render them intrinsic dietary components due to their common occurrence in plants. Now-a-days, polyphenols (secondary metabolites) are characterized by a vast spectrum of physiological significance. From the past twenty years in the world of scientific research, polyphenols play an important role in a wide range of physiological processess. This review focuses on the development of polyphenols as antitumor agent in recent research studies.
  • Drug design, synthesis and in vitro evaluation of substituted benzofurans as hsp90 inhibitors
    Sundeep Kadasi, Thadeu E.M.M. Costa, Neha Arukala, Mallika Toshakani, Chaitanya Duggineti, Sreekanth Thota, Sayan D. Gupta, Shiva Raj, Carmen Penido, Maria G. Henriques, Nulgumnalli M. Raghavendra
    Medicinal Chemistry, 2018
    BACKGROUND Heat shock protein 90 is a molecular chaperone required for the stability and function of several client proteins that promote cancer cell growth and/or survival. Discovery of Hsp90 inhibitors has emerged as an attractive target of research in cancer therapeutics. Natural products like geldanamycin and radicicol are established Hsp90 inhibitors, but face limitations with toxicity and inactivity, by in vivo studies respectively. However, they lay the logical starting point for the design of novel synthetic or semi-synthetic congeners as Hsp90 inhibitors. OBJECTIVE In this article, the structure based drug design of substituted 2-aryl/heteroarylidene-6- hydroxybenzofuran-3(2H)-one analogues to optimize and mimic the pharmacophoric interactions of the valid Hsp90 inhibitor radicicolis focused. METHOD In silico docking study was performed by Surflex dock-Geom (SYBYL- X 1.2 drug discovery suite) and the designed ligands were chemically synthesized by conventional method using resorcinol and chlororesorcinol as starting materials. Two dimensional chemical similarity search was carried out to identify the chemical space of 'SY' series in comparison with reported Hsp90 inhibitors. The in vitro cell proliferation assay (resazurin reduction method) and proteomic investigation (DARTS) was carried out on whole cell lysate to evaluate anticancer activity. RESULTS The chemical structures of all the synthesized compounds were confirmed by IR, 1H-NMR and Mass spectral analysis. The results of chemical similarity search show that SY series fit it in the chemical space defined by existing Hsp90 inhibitors. In vitro cell proliferation assay, against human melanoma and breast cancer cell lines, identified 'SY3' as the promising anticancer agent amongst the series. CONCLUSION Docking studies, 2D chemical similarity search, resazurin reduction assay and qualitative proteomic analysis identify 'SY3'as a promising Hsp90 inhibitor amongst the series.
  • Metal Nanoparticles: Synthesis and Applications in Pharmaceutical Sciences
    Sreekanth Thota, Debbie C. Crans
    Metal Nanoparticles Synthesis and Applications in Pharmaceutical Sciences, 2017
    A much-needed summary of the importance, synthesis and applications of metal nanoparticles in pharmaceutical sciences, with a focus on gold, silver, copper and platinum nanoparticles. After a brief introduction to the history of metal complexes in medicine and fundamentals of nanotechnology, the chapters continue to describe different methods for preparation of metal nanoparticles. This section is followed by representative presentations of current biomedical applications, such as drug delivery, chemotherapy, and diagnostic imaging.
  • Introduction
    Sreekanth Thota, Debbie C. Crans
    Metal Nanoparticles Synthesis and Applications in Pharmaceutical Sciences, 2017
  • Overview of chemical drug design
    Chemical Drug Design, 2016
  • Design, synthesis, structural characterization and in vitro cytotoxic activity of mononuclear Ru(II)complexes
    Sreekanth Thota, Srujana Vallala, Rajeshwar Yerra, Daniel Alencar Rodrigues, Eliezer J. Barreiro
    Medicinal Chemistry Research, 2016
  • Beyond the selective inhibition of histone deacetylase 6
    Daniel A. Rodrigues, Sreekanth Thota, Carlos A.M. Fraga
    Mini Reviews in Medicinal Chemistry, 2016
  • Anticancer ruthenium complexes in drug discovery and medicinal chemistry
    Sreekanth Thota
    Mini Reviews in Medicinal Chemistry, 2016
  • Drug discovery and development of antimalarial agents: Recent advances
    Sreekanth Thota, Rajeshwar Yerra
    Current Protein and Peptide Science, 2016
  • Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes
    Sreekanth Thota, Srujana Vallala, Rajeshwar Yerra, Daniel Alencar Rodrigues, Nulgumnalli Manjunathaiah Raghavendra, Eliezer J. Barreiro
    International Journal of Biological Macromolecules, 2016
  • Recent advances in synthetic chemistry of diabetic research
    Sreekanth Thota, Carlos Morel
    Mini Reviews in Medicinal Chemistry, 2015
  • Design, synthesis, characterization, antioxidant and in vitro cytotoxic activities of novel coumarin thiazole derivatives
    Sreekanth Thota, Kavitha Nadipelly, Anusha Shenkesi, Rajeshwar Yerra
    Medicinal Chemistry Research, 2015
  • Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes
    Sreekanth Thota, Srujana Vallala, Rajeshwar Yerra, Eliezer J. Barreiro
    Chinese Chemical Letters, 2015
  • Synthesis of thiocarbohydrazide and carbohydrazide derivatives as possible biologically active agents
    Kiran Gangarapu, Sarangapani Manda, Anvesh Jallapally, Sreekanth Thota, Subhas S. Karki, Jan Balzarini, Erik De Clercq, Harukuni Tokuda
    Medicinal Chemistry Research, 2014
  • Synthesis, cytostatic and antiviral activity of some ruthenium (II) complexes
    Turkish Journal of Pharmaceutical Sciences, 2014
  • Synthesis, spectroscopic characterization, in vitro cytotoxic and structure activity relationships of some mononuclear Ru(II) complexes
    Sreekanth Thota, Srujana Vallala, Mohammad Imran, Sravani Mekala, Shyam Sunder Anchuri, Subhas Somalingappa Karki, Rajeshwar Yerra, Jan Balzarini, Erik De Clercq
    Journal of Coordination Chemistry, 2013
  • Antinociceptive and antitumor activity of novel synthetic mononuclear Ruthenium (II) compounds
    Journal of Research in Medical Sciences, 2013
  • Antimicrobial and antimalarial activity of novel synthetic mononuclear Ruthenium(II) compounds
    Shyam Sunder Anchuri, Sreekanth Thota, Raja Narender Bongoni, Rajeshwar Yerra, Rama Narsimha Reddy, Satyavati Dhulipala
    Journal of the Chinese Chemical Society, 2013
  • Synthesis, antimicrobial screening and beta lactamase inhibitory activity of 3-(3-chloro-4-fluorophenylimino) indolin-2-on and 5-chloro indolin-2-on derivatives
    Turkish Journal of Pharmaceutical Sciences, 2012
  • Microwave assisted synthesis, characterization of some new isatin and thiophene derivatives as cytotoxic and chemopreventive agents
    Kiran Gangarapu, Sarangapani Manda, Sreekanth Thota, Rajeshwar Yerra, Subhas S. Karki, Jan Balzarini, Erik De Clercq, Harukuni Tokuda
    Letters in Drug Design and Discovery, 2012
  • Synthesis, spectroscopic characterization, antineoplastic, in vitro-cytotoxic, and antibacterial activities of mononuclear ruthenium(II) complexes
    Sreekanth Thota, Mohammad Imran, Manasa Udugula, Subhas Somalingappa Karki, Narasimha Kanjarla, Rajeshwar Yerra, Jan Balzarini, Erik De Clercq
    Journal of Coordination Chemistry, 2012
  • In vitro antioxidant activity of some novel synthetic mononuclear ruthenium (II) compounds
    Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala
    Letters in Drug Design and Discovery, 2012
  • Synthesis, spectroscopic characterization and in vitro antitumor activities of some novel mononuclear Ru(II) complexes
    Sreekanth Thota, Mohammad Imran, Manasa Udugula, Rajeshwar Yerra, Subhas S. Karki, Jan Balzarini, Erik De Clercq
    Chinese Chemical Letters, 2012
  • Novel mononuclear ruthenium(II) compounds in cancer therapy
    Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Krishna Prasad Devarakonda, Satyavati Dhulipala
    Asian Pacific Journal of Cancer Prevention, 2012
  • Synthesis, characterization and cytotoxic activity of some Ru(II) complexes
    Turkish Journal of Pharmaceutical Sciences, 2011
  • Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes
    Sreekanth Thota, Subhas Somalingappa Karki, K.N. Jayaveera, Jan Balzarini, Erik De Clercq
    Journal of Coordination Chemistry, 2010
  • Synthesis and cytotoxic activity of some mononuclear Ru(II) Complexes
    Research Journal of Pharmaceutical Biological and Chemical Sciences, 2010
  • Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes
    Sreekanth Thota, Subhas S. Karki, K. N. Jayaveera, Jan Balzarini, Erik De Clercq
    Journal of Enzyme Inhibition and Medicinal Chemistry, 2010
  • Synthesis, characterization and antibacterial activity of some novel mononuclear Ru(II) complexes
    International Journal of Pharmacy and Pharmaceutical Sciences, 2009
  • Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds
    Subhas S. Karki, Sreekanth Thota, Satyanarayana Y. Darj, Jan Balzarini, Erik De Clercq
    Bioorganic and Medicinal Chemistry, 2007

RECENT SCHOLAR PUBLICATIONS

  • PROTACs: Next-Generation Cancer Therapeutics Revolutionizing Targeted Treatment Strategies
    U Sireen, S Thota, S Sriram, N Amreen, D Kumaraswamy, S Katherashala
    In Silico Research in Biomedicine, 100386 , 2026
    2026
  • Machine Learning Modeling of D-Optimal Design Data for Metformin Hydrochloride Orally Disintegrating Tablets
    S Yarlagadda, V Kumar, S Sriram, N Ahmad, S Solanki, N Solanki, ...
    2026
  • Explainable Machine Learning Using Taguchi-QbD Data for Digital Design Space Mapping of Pregabalin Extended-Release Tablets
    TS Walia, S Sriram, N Ahmad, S Solanki, N Solanki, JM Kalra, Y Shravan, ...
    2026
  • PROTACs: Next-Generation Cancer Therapeutics Revolutionizing Targeted Treatment Strategies
    Uzma Sireen, Sreekanth Thota, Neha Amreen, Damerakonda Kumaraswamy ...
    Insilico Research in Biomedicine , 2026
    2026
  • Decision-Centric Explainable AI for QbD Optimization of Ultrasound-Triggered Drug-Loaded Microbubbles and Control Strategy Development
    AL Yadav, S Solanki, N Solanki, V Patil, S Sriram, Y Kumar, S Thota, ...
    2026
  • From QbD to Explainable AI: Interpretable Random Forest Surrogates for Design Space Understanding of Voriconazole–β-Cyclodextrin Inclusion Complexes
    S Solanki, G Kumari, N Solanki, D Jindal, GU Kiranmai, S Chakorkar, ...
    2026
  • Ultrasound-responsive doxorubicin microbubbles engineered by QbD: enhanced in vitro anti-breast-cancer efficacy with attenuated cardiac cell toxicity
    KL Dr. Sonal Solanki, Dr. Sreekanth Thota, Dr. Nikunj Solanki, Dr. Mahesh ...
    BMC Pharmacology & Toxicology , 2026
    2026
  • Development and validation of new analytical methods for the simultaneous estimation of Ramipril and Hydrochlorthiazide in bulk drug and pharmaceutical Formulations by RP-HPLC.
    TS Pokala Pravalika, Damerakonda Kumara Swamy, Sai Krishna Guduru
    World Journal of Pharmaceutical Research 14 (23), 678-692 , 2025
    2025
  • In-Vitro Pharmacological Evaluation of various parts of Couroupita Guianensis
    DKS Ch. Rahul, Thota Sreekanth, Karka Srinivas Reddy, Neha Amreen
    European Journal of Pharmaceutical and Medical Research 12 (11), 427-434 , 2025
    2025
  • Guardians of Purity: In-Process Quality Control in Herbal and Synthetic Antifungal Medicines
    KSR Damerakonda Kumara Swamy, Thummala Gowri Priya, Sreekanth Thota, Ch Rajveer
    International Journal of Pharmacy and Biological Sciences 15 (3), 60-63 , 2025
    2025
  • Collaborative filtering and knowledge graphs for data discovery
    SR Thota, S Arora
    International Research Journal of Modern Engineering and Technology Science … , 2024
    2024
    Citations: 7
  • Design, Synthesis and Pharmacological Evaluation of First‐in‐Class Multitarget N‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors
    DARFSGFSSP de Sena M. Pinheiro Marina A. Alves Sreekanth Thota Lorrane S ...
    ChemMedChem , 2020
    2020
    Citations: 46
  • Structure–property relationship studies of 3-acyl-substituted furans: the serendipitous identification and characterization of a new non-classical hydrogen bond donor moiety
    DA Rodrigues, MP Pedro de Sena, FS Sagrillo, MCR Freitas, MA Alves, ...
    New Journal of Chemistry 44 (26), 10994-11005 , 2020
    2020
    Citations: 6
  • The use of conformational restriction in medicinal chemistry
    P de Sena M Pinheiro, DA Rodrigues, R do Couto Maia, S Thota, ...
    Current topics in medicinal chemistry 19 (19), 1712-1733 , 2019
    2019
    Citations: 64
  • Recent Advances in Development of Polyphenols as Anticancer Agents
    S Thota, DA Rodrigues, EJ Barreiro
    Mini Reviews in Medicinal Chemistry 18 (15), 1265-1269 , 2018
    2018
    Citations: 14
  • N-Acylhydrazones as drugs
    S Thota, DA Rodrigues, PSM Pinheiro, LM Lima, CAM Fraga, EJ Barreiro
    Bioorganic & Medicinal Chemistry Letters 28 (17), 2797-2806 , 2018
    2018
    Citations: 247
  • Structural basis for the agonist action at free)
    DA Rodrigues, PSM Pinheiro, TTSC Ferreira, S Thota, CAM Fraga
    Chemical Biology & Drug Design 91 (3), 668-680 , 2018
    2018
    Citations: 19
  • Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
    S Thota, DA Rodrigues, DC Crans, EJ Barreiro
    Journal of Medicinal Chemistry 61 (14), 5805-5821 , 2018
    2018
    Citations: 524
  • Methods for preparation of metal nanoparticles
    S Iravani, S Thota, DC Crans
    Metal nanoparticles: synthesis and applications in pharmaceutical sciences … , 2018
    2018
    Citations: 31
  • Metal Nanoparticles: Synthesis and Applications in Pharmaceutical Sciences
    S Thota, DC Crans
    John Wiley & Sons , 2018
    2018
    Citations: 105

MOST CITED SCHOLAR PUBLICATIONS

  • Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
    S Thota, DA Rodrigues, DC Crans, EJ Barreiro
    Journal of Medicinal Chemistry 61 (14), 5805-5821 , 2018
    2018
    Citations: 524
  • N-Acylhydrazones as drugs
    S Thota, DA Rodrigues, PSM Pinheiro, LM Lima, CAM Fraga, EJ Barreiro
    Bioorganic & Medicinal Chemistry Letters 28 (17), 2797-2806 , 2018
    2018
    Citations: 247
  • Metal Nanoparticles: Synthesis and Applications in Pharmaceutical Sciences
    S Thota, DC Crans
    John Wiley & Sons , 2018
    2018
    Citations: 105
  • Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds
    SS Karki, S Thota, SY Darj, J Balzarini, E De Clercq
    Bioorganic & Medicinal Chemistry 15 (21), 6632-6641 , 2007
    2007
    Citations: 94
  • EDITORIAL (thematic issue: treatment and diagnosis of diabetes mellitus and its complication: advanced approaches)
    S Sen, R Chakraborty
    Mini reviews in medicinal chemistry 15 (14), 1132-1133 , 2015
    2015
    Citations: 76
  • The use of conformational restriction in medicinal chemistry
    P de Sena M Pinheiro, DA Rodrigues, R do Couto Maia, S Thota, ...
    Current topics in medicinal chemistry 19 (19), 1712-1733 , 2019
    2019
    Citations: 64
  • Synthesis of thiocarbohydrazide and carbohydrazide derivatives as possible biologically active agents
    K Gangarapu, S Manda, A Jallapally, S Thota, SS Karki, J Balzarini, ...
    Medicinal Chemistry Research 23 (2), 1046-1056 , 2014
    2014
    Citations: 56
  • Design, Synthesis and Pharmacological Evaluation of First‐in‐Class Multitarget N‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors
    DARFSGFSSP de Sena M. Pinheiro Marina A. Alves Sreekanth Thota Lorrane S ...
    ChemMedChem , 2020
    2020
    Citations: 46
  • Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru (II) complexes
    S Thota, S Vallala, R Yerra, DA Rodrigues, NM Raghavendra, EJ Barreiro
    International Journal of Biological Macromolecules 82, 663-670 , 2016
    2016
    Citations: 44
  • Design, synthesis, characterization, antioxidant and in vitro cytotoxic activities of novel coumarin thiazole derivatives
    S Thota, K Nadipelly, A Shenkesi, R Yerra
    Medicinal Chemistry Research 24 (3), 1162-1169 , 2015
    2015
    Citations: 36
  • Methods for preparation of metal nanoparticles
    S Iravani, S Thota, DC Crans
    Metal nanoparticles: synthesis and applications in pharmaceutical sciences … , 2018
    2018
    Citations: 31
  • Beyond the selective inhibition of histone deacetylase 6
    D A Rodrigues, S Thota, C AM Fraga
    Mini Reviews in Medicinal Chemistry 16 (14), 1175-1184 , 2016
    2016
    Citations: 26
  • Microwave assisted synthesis, characterization of some new isatin and thiophene derivatives as cytotoxic and chemopreventive agents
    K Gangarapu, S Manda, S Thota, R Yerra, S S Karki, J Balzarini, ...
    Letters in Drug Design & Discovery 9 (10), 934-941 , 2012
    2012
    Citations: 26
  • Novel mononuclear ruthenium (II) compounds in cancer therapy
    SS Anchuri, S Thota, R Yerra, KP Devarakonda, S Dhulipala
    Asian Pacific Journal of Cancer Prevention 13 (7), 3293-3298 , 2012
    2012
    Citations: 25
  • Synthesis, spectroscopic characterization, antineoplastic, in vitro-cytotoxic, and antibacterial activities of mononuclear ruthenium (II) complexes
    S Thota, M Imran, M Udugula, SS Karki, N Kanjarla, R Yerra, J Balzarini, ...
    Journal of Coordination Chemistry 65 (5), 823-839 , 2012
    2012
    Citations: 22
  • Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes
    S Thota, SS Karki, KN Jayaveera, J Balzarini, ED Clercq
    Journal of Enzyme Inhibition and Medicinal Chemistry 25 (4), 513-519 , 2010
    2010
    Citations: 21
  • Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru (II) complexes
    S Thota, S Vallala, R Yerra, EJ Barreiro
    Chinese Chemical Letters 26 (6), 721-726 , 2015
    2015
    Citations: 20
  • Structural basis for the agonist action at free)
    DA Rodrigues, PSM Pinheiro, TTSC Ferreira, S Thota, CAM Fraga
    Chemical Biology & Drug Design 91 (3), 668-680 , 2018
    2018
    Citations: 19
  • Drug Discovery and Development of Antimalarial Agents: Recent Advances.
    S Thota, R Yerra
    Current Protein & Peptide Science 17 (3), 275-279 , 2016
    2016
    Citations: 17
  • Synthesis, spectroscopic characterization, in vitro cytotoxic and structure activity relationships of some mononuclear Ru (II) complexes
    S Thota, S Vallala, M Imran, S Mekala, SS Anchuri, SS Karki, R Yerra, ...
    Journal of Coordination Chemistry 66 (6), 1031-1045 , 2013
    2013
    Citations: 17

Publications

Books & Book Chapters:

1. Thota S, Crans DC. “Metal Nanoparticles: Synthesis and Applications in Pharmaceutical Sciences”
Wiley-VCH Verlag GmbH & Co. KGaA, Germany, 2018, ISBN: 978-3-527-33979-2. Direct Link

2. Thota S, Crans DC. Introduction: “Metal Nanoparticles: Synthesis and Applications in Pharmaceutical Sciences”
Wiley-VCH Verlag GmbH & Co. KGaA, Germany, 2018, Book Chapter, Direct Link


Research Publications (In peer-reviewed journals):

1. Rodrigues DA, Pinheiro PSM, Sagrillo FS, Ramalho-Freitas MC, Alves MA, Thota S, Tinoco L, Magalhães A, Sant'Anna, CMR, Fraga CAM. Structure-Property Relationship Studies of 3-Acyl-Substituted Furans: The Serendipitous Identification and Characterization of a New Non-Classical Hydrogen Bond Donor Moiety. New J Chem. 2020; 44: 10994-11005. Direct Link

2. Rodrigues DA, Guerra FS, Sagrillo FS, Pinheiro PSM, Alves MA, Thota S, Chaves LS, Sant’Anna CMR, Fernandes PD, Fraga
CAM. Design, Synthesis and Pharmacological Evaluation of First‐in‐Class Multitarget N‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. Chem Med Chem. 2020; 15(6): 539-551. Direct Link

3. Kadasi S, Costa TEMM, Arukala, N, Toshakani M, Duggineti C, Thota S, Gupta SD, Raj S, Penido C, Henriques MG, Raghavendra NM. “Drug design, synthesis and in vitro evaluation of substituted benzofurans as Hsp90 inhibitors’’ Med Chem. 2018; 14(1): 44-52. Direct Link

4. Thota S, Vallala S, Yerra R, Rodrigues DA, Raghavendra NM, Barreiro EJ. "

GRANT DETAILS

2014 CAPES-Fiocruz Senior Postdoctoral Researcher award grant, Fiocruz, Rio de Janeiro, Brazil
2013 Research Scholar, Colorado state University, Colorado, USA
2011 Research Promotion Scheme grant, AICTE, New Delhi, India

RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)

Published Patents: 3

1. AI BASED DEVICE FOR DOCKING AND RECEPTOR TARGETING
2. DEVICE FOR ISOLATION AND ESTIMATION OF MEDICINAL PLANTS EXTRACT
3. SUSTAINABLE-POLYMER BASED COMPOSITES FOR WATER PURIFICATION APPLICATIONS

Industry, Institute, or Organisation Collaboration

Collaborative Research:

Professional Appointments:
January-2023 to till date Professor, Nethaji Institute of Pharmaceutical Sciences, Warangal (T.S).
August-2018 to December-2022 Professor, Tirumala College of Pharmacy, Nizamabad, Telanagana.
September-2014 to August-2018 Visiting Researcher, Fiocruz & UFRJ, Rio de Janeiro, Brazil.
2013-2014 Associate Professor, S. R. College of Pharmacy, Kakatiya University, Warangal, India.
2013 Research Scholar, Colorado State University, Colorado, Fort Collins, USA.
2010-2013 Associate Professor, S. R. College of Pharmacy, Kakatiya University, Warangal, India.
2008-2010 Assistant Professor, S. R. College of Pharmacy, Kakatiya University, Warangal, India.
2006-2008 Assistant Professor, Blue birds College of Pharmacy, Kakatiya University, Warangal
1. INCT-IDN, National Institute of Science and Technology of innovation in neglected diseases. Rio de Janeiro, Brazil.
2. National Institute of Health, Bethesda, USA.
3. Prof. Eliezer J. Barreiro, LASSBio, UFRJ, Cidade Universitaria, Rio de Janeiro, Brazil.
4. Prof. Dr. Erick De Clercq, Rega Institute for Medical Research, Leuven, Belgium.